Please login to the form below

Not currently logged in
Email:
Password:

Intuniv

This page shows the latest Intuniv news and features for those working in and with pharma, biotech and healthcare.

Shire separates out neuroscience as it considers its future

Shire separates out neuroscience as it considers its future

The company’s new neuroscience division will look to build on its ADHD heritage and newer products like Intuniv, Vyvanse and Mydayis, the latter of which was recently launched in the

Latest news

More from news
Approximately 3 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Challenging perceptions Challenging perceptions

    Shire also has a foot in the non-stimulant camp with Intuniv (guanfacine), which was approved in Europe in September having been available in the US for some time - long enough

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics